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Abstract 
Angiogenesis is a critical factor in tumor growth and metastasis, and microvessel density 
(MVD) was an important parameter for assessing vessels in tumors. However, radiologic 
assessment of tumor vascularity is not yet well established. In our study, we aimed at inves-
tigating the efficacy of contrast-enhanced ultrasonography (CEUS) in exploring the vascularity 
of the ovarian tumors or tumor-like lesions to assess the relationship between the parameters 
of the peak intensity (PI) and area under curve (AUC) on CEUS and MVD in ovarian masses. 
Compared to the contrast-enhanced ultrasound technique, conventional ultrasound shows 
limitation in differentiating benign and malignant ovarian tumors. The former is promising in 
improving the sensitivity of detecting small vessels and blood flow in ovarian tumors. Our 
results showed clear differences in enhancement patterns between benign and malignant 
ovary tumors or tumor-like lesions. The PI and AUC in the malignant tumors were signifi-
cantly higher than those in the benign tumors or tumor-like lesions (p=0.001 and =0.01, 
respectively). The MVD was 43.1 ± 20.4 in the benign tumors or tumor-like lesions and was 
65.3 ± 22.3 in the malignant ones (p= 0.01). In both the benign and malignant groups, the PI 
and AUC were correlated significantly with the MVD (r=0.595, p = 0.001; r =0.533, p = 0.003, 
respectively). The PI and AUC in CEUS can reflect the MVD in ovarin tumors. The PI and 
AUC of the ovarian masses in the contrast transvaginal sonography show significant corre-
lation with the angiogenesis and may help in assessing tumor vascularity in ovarian masses. 
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Introduction 
Ovarian  cancer  is  the  leading  cause  of  death 
from  gynecological  malignancy  and  the  fifth  most 
common  cause  of  cancer-related  death  in  women. 
Angiogenesis is a critical factor for tumor growth and 
metastasis in a variety of human tumors, including 
ovarian  cancer  [1-4].  Therefore,  studying  the  tumor 
angiogenesis and microvessel density (MVD) can help 
to assess the prognosis of cancer patients [5-6]. Cur-
rently, imaging techniques such as CT, MRI, and ul-
trasound have been widely used in preoperative di-
agnosis  of  ovarian  tumors  [7,  8].  Thereinto,  ultra-
sound is a convenient imaging technique. Owing to 
the  lack  of  reflection  from  red  blood  cells  and  low 
signal to noise ratio, conventional transvaginal color 
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Doppler ultrasound shows limitation in differentiat-
ing ovarian tumors with similar acoustic properties, 
relatively low and small blood vessels, and slow flow 
[9-11]. CEUS has been used preoperatively in diag-
nosing ovarian tumor as well as for correlating ultra-
sound characteristics and tumor angiogenesis [12-18]. 
In 1994, Suren [19] reported that Levovist (Schering, 
Berlin, Germany) succeeded in enhancing the Doppler 
signal  strength  in  small  ovarian  tumors.  Ten  years 
later,  Testa  et  al.  [20]  reported  the  utitility  of  se-
cond-generation ultrasound contrast agent SonoVue 
(Bracco,  Italy)  during  transvaginal  ultrasound  for 
differentiating benign and malignant ovarian masses 
in  33  patients.  In  their  study  [20],  CEUS  was  more 
accurate in displaying a microvascular bed than con-
ventional  Droppler  imaging  and  therefore  showed 
better differentiation ability than the latter.  
Studies on angiogenesis of ovarian cancer have 
demonstrated  a  significant  correlation  of  the  angio-
genesis with the prognosis in ovarian cancer [21, 22]. 
Xie et al [23] found that the peak velocity of ovarian 
tumor blood flow as detected by CDFI was positively 
correlated with MVD, reflecting the tumor angiogen-
esis status.  So far, there have been only few reports on 
transvaginal CEUS characteristics and their relation-
ship with MVD in benign and malignant ovarian le-
sions.  Our  study  aimed  at  analyzing  the  CEUS  pa-
rameters and their relations to MVD detected by im-
munohistochemistry  in  62  ovarian  benign  and  ma-
lignant tumors or tumor-like lesions.  
 
Materials and methods  
Patient selection 
Sixty-two  patients  (mean  age  43.2±3.9  years, 
range 38-74 years) who were diagnosed to have an 
ovarian mass that was difficult to confirm by conven-
tional ultrasound in our hospital from October 2005 to 
March 2010 were enrolled in this study. All these pa-
tients  received  a  contrast-enhanced  transvaginal  ul-
trasound  to  identify  the  characteristics  and  tumor 
angiogenesis.  
Ultrasound examination  
CEUS was performed with an Acuson Sequoia 
512  ultrasound  system  (Siemens  Medical  Solutions, 
Mountain View, CA),  contrast pulse sequence (CPS), 
real-time ultrasound imaging software, and EV8-C4 
(4-8 MHz) endovaginal probe.  
The  following  procedures  were  performed:  (1) 
recording of the ovarian mass size, echo characteris-
tics,  border,  color  Doppler  flow  distribution  with 
conventional transvaginal ultrasound and color Dop-
pler scale; (2) determination of the angiographic tar-
get:  ultrasound  image  analysis  performed  for  one 
ovarian mass side with unclear diagnosis or typical 
lesions;  (3)  selection  of  the  plane  with  solid  lesion 
part, thick cyst wall, a cavity containing papilla, or the 
most abundant blood supply indicated by CDFI as the 
best  imaging  observation  view,  then  switching  to 
contrast pulse sequencing (CPS) with low mechanical 
index (MI) ranging from 0.12 to 0.16 (the radio fre-
quency  signal,  log  values  and  pixel  density  were 
used). The probe in all the procedures was maintained 
in the same position; (4) All patients received injec-
tions  of  a  sulfur  hexafluoride  ultrasound  contrast 
agent (SonoVue; Bracco SpA, Milan, Italy). The agent 
(25 mg) was shaken for about 1 minute with 5 mL of 
0.9% saline solution, and 4.8 mL of this suspension 
was injected as a bolus manually through an 18-gauge 
cannula placed in the antecubital vein. Then 5 mL of a 
0.9% saline flush was injected. Seven seconds after the 
blush count time started, the real-time enhancement 
pattern  of  contrast  agent  inside  the  tumor  was  ob-
served  for  3-5  minutes  and  the  imaging  video  was 
recorded. After scanning, the video was replayed and 
the  area  with  significant  contrast  enhancement  was 
chosen as the ROI which was manually outlined. The 
time-intensity curve (TIC) was drawn automatically 
with  quantitative  imaging  analysis  software  (Ax-
iusTM auto tracking contrast quantification, ACQ) to 
obtain  the  following  parameters  under  intra-lesion 
contrast perfusion: arrival time (AT), peak intensity 
(PI), time to peak intensity (TTP), and the area under 
the curve (AUC).  Data were processed in the same 
conditions with the same ultrasound system. The en-
hancement patterns and TIC results were analyzed by 
two physicians.  
Immunohistochemistry  
The ovarian tumors or tumor-like lesions surgi-
cally removed were embedded in paraffin, sectioned, 
and immunohistochemically stained for CD34 with a 
monoclonal mouse anti-human antibody (Dako Rea-
gent  Company,  Carpinteria,  CA,  USA).  A  positive 
control (known ovarian cancer section) and a negative 
control (PBS instead of primary antibody) were used 
for all stains. Positive CD34 staining was seen in the 
cytoplasm  of  vascular  endothelial  cells. 
Brown-stained individual vascular endothelial cells or 
endothelial  cell  clusters  were  counted  as  one  mi-
crovessel. Vasculature with significant smooth muscle 
wall  and  lumen  greater  than  the  diameter  of  eight 
blood vessels were not counted.  
The  MVD  was  determined  by  the  modified 
quantification method as reported by Weidner et al 
[24]. Five fields of the most MVD expression particles 




counted  at  higher  magnification  (×  200).  The  mean 
MVD value was calculated.  
Statistical analysis  
SPSS 16.0 statistical software was used for data 
analysis. Quantitative data was expressed as ( s x ). 
An  independent  sample  t-test  was  used  to  compare 
the  differences  between  the  two  groups.  The  ultr a-
sound parameters and MVD in benign and malignant 
ovarian tumors or tumor-like lesions were compared 
using  bi-variant  correlation  analysis. p  <  0.05  was 
considered statistically significant.  
Results and Discussion 
The contrast peak intensity, area under the 
curve in ovarian tumor 
According to the surgical laparoscopic and  ul-
trasound-guided biopsy result, the patients were di-
vided into benign and malignant groups. The benign 
group  (n=36,  58.1%)  included  serous  papillary 
cystadenoma  (n=6),  serous  papillary  adenofibroma 
(n=4),  endometriosis  (n=5),  mature  teratoma  (n=5 
including  1  struma  ovarii),  fibrothecomatous  tumor 
(n=9), steroid cell tumor (n=1), ovarian abscess (n=1), 
and corpus luteum cyst (n=5).  The malignant group 
(n=26,  41.9%)  included  serous  papillary  carcinoma 
(n=14,  2  bilateral),  endometrioid  adenocarcinoma 
(n=2), clear cell carcinoma (n=2), fibrosarcoma (n=1), 
and metastatic carcinoma (n=7, 5 bilateral). The mean 
diameter of these masses was 4.4 ± 2.1cm (range 1.7 to 
9.3cm), and 38.7% (24/62) of them were less than 3cm 
in diameter, and 50.0% (31/62) less than 5cm in di-
ameter. 
Our study showed that in benign tumors or tu-
mor-like  lesions,  CEUS  ring-like  enhancement  was 
seen in cystic wall and/or papillae of the ovarian cyst 
and abscess, while solid tumors or tumor-like lesions 
showed either internal scattered mild enhancement or 
branching  regular  moderate  low  enhancement.  In 
malignant  tumors,  CEUS  showed  overall  heteroge-
neous  enhancement  or  dendritic,  rapidly  increased 
enhancement. CEUS parameters mainly included PI, 
AT, TTP and AUC. PI and AUC indicated enhance-
ment  intensity,  AT  and  TTP  were  related  to  en-
hancement time. In this study, the CEUS parameters 
of  both  benign  and  malignant  ovarian  tumors  and 
tumor-like lesions as well as the TIC were shown in 
Figures (1A-E, 2A-E) and Table 1. PI and AUC were 
significantly higher in malignant tumors than those in 
the benign group (p=0.001 and p=0.01, respectively), 
which suggested that malignant ovarian tumors were 
rich in blood perfusion. 
Table 1. Comparison of TIC parameters between benign 
and malignant tumors ( s x ) 
Group  Case  AT(s)  TTP(s)  PI (dB)  AUC 
benign  36  16.4 ± 4.0  27.6 ± 6.6  12.0 ± 6.8  8.8 ± 6.1 
malignant  26  13.3 ± 4.8  22.2 ± 6.5  18.3 ± 5.7  17.1 ± 6.5 
p-value    0.017  0.006  0.001  0.01 
 
 
MVD and its relation with CEUS parameters in 
ovarian tumors  
The MVD by immunohistochemical assessment 
was 43.1 ± 20.4 in the benign tumors or tumor-like 
lesions, significantly lower than 65.3 ± 22.3 in the ma-
lignant ones (p=0.002, Figures 1F & 2F).  PI and AUC 
were positively correlated with MVD in both benign 
and malignant groups (r=0.595 and r =0.533; p = 0.001 
and p = 0.003, respectively; Figures 3A-B). The MVD 
difference between benign and malignant tumors was 
correlated with vascular endothelial cell activity and 
angiogenesis-related features inside tumors [25]. We 
also found that vascular density changes were signif-
icantly  different  in  benign  and  malignant  groups.  
MVD  was  well  correlated  with  tumor  tissue  blood 
perfusion  in  both  groups,  suggesting  that  the  in-
creased  malignant  tumors  MVD  can  increase  blood 
volume.  
There were few limitations in our study. First, 
some  benign  ovarian  tumors  or  tumor-like  lesions 
with more blood vessels might show the same ultra-
sound  characteristics  as  the  malignant  tumors.  Se-
cond, although microvessels in both benign and ma-
lignant lesions were different, their number and dis-
tribution  might  overlap.  In  our  study,  one  case  of 
ovarian  abscess  and  one  corpus  luteum  cyst  also 
showed a rapid enhancement and similar CEUS pa-
rameters as malignant tumors. This may be related to 
the increase of blood supply from increased inflam-
matory granulation tissue in the abscess wall, angio-
genesis,  and  higher  perfusion  due  to  an  increased 
estrogen level in the ovarian luteal phase. However, 
in the above cases, the circle enhancement was shown 
in the cystic wall, which was different from that in 
malignant  tumors.  The  rapid  enhancement  was 
shown only in the cystic wall of the abscess and cor-
pus luteum cyst, not in solid-like incomplete abscess 
liquefaction  and  cystic  wall  pseudopapillae  of  the 
corpus  luteum  cyst.  In  addition,  the  papillary  en-
hancement pattern in one case of struma ovarii over-
lapped with malignant tumors, and one clear cell car-
cinoma overlapped with benign tumors. More studies 
are needed to investigate its contrast-enhanced ultra-




ovarian cancer is usually accompanied by metastasis 
in omentum, peritoneum and lymph node et al. which 
are helpful features for differentiating them from be-
nign lesions. Finally, the contrast-enhanced imaging 
parameters of benign and malignant ovarian lesions 
seldom  partially  overlapped.  Therefore,  proper  di-
agnosis should be based on the comprehensive clini-
cal data analysis, conventional sonographic features 
and enhanced ultrasound imaging.  
In summary, PI and AUC on CEUS can be ap-
plied  to  evaluate  vessels  in  ovarian  tumors  or  tu-
mor-like lesions and can provide noninvasive param-
eters for clinical evaluation of tumor vascularity.   
 
 
Figure 1. The CEUS and MVD of a thecoma of the ovary. (A) Two-dimensional transvaginal ultrasound showed a heter-
ogeneous hypoechoic mass (3.9 cm × 3.7 cm × 2.7 cm) in the left ovary. (B) Little scattered blood flow signal could be seen 
in CDFI. (C) CEUS showed slightly scattered enhancement within the ovarian tumor, earlier than surrounding ovarian tissue, 
the peak intensity of 11.88 dB, lower than 18.39 dB of the surrounding ovarian tissue. (Arrows indicate the mass and the 
boundaries of the ovary). (D)A region of interest (ROI) was taken from the mass and ovary respectively. (White ROI 1: the 
region of interest within the mass, blue ROI 2: region of interest within the ovarian tissue), drawing TIC (white and blue 
curves represent the TIC of the mass and ovary). (E)TIC showed AT 21.97 seconds, TTP 32.63 seconds, PI 11.88 dB, AUC 
10.60, ROI 2 for the ovarian tissue: AT 24.20 seconds, TTP 40.41 seconds, PI 18.39 dB. AUC 18.04. (F) MVD (CD34 
immunohistochemical staining, magnification 200×), scarce interstitial microvessels.  







Figure 2. The CEUS and MVD of a poorly -differentiated serous adenocarcinoma of the ovary. (A) Two-dimensional 
transvaginal ultrasound showed a hypoechoic mass (4.9 cm × 3.0 cm × 3.3 cm) in the left adnexa with a clear boundary and 
heterogeneous echo. (B) Abundant blood flow signals can be seen in CDFI. (C) After 11.8 seconds of contrast agent in-
jection, a rapid high enhancement can be seen. (D) A region of interest (ROI) within the tumor was taken to draw a TIC 
(white curve represents the tumor TIC). (E) The tumor TIC showed that AT was 11.8 seconds, TTP 18.41 seconds, PI is 
26.64 dB, AUC 25.95. (F) MVD showed significantly increased interstitial microvessels (CD34, immunohistochemical 





Figures 3. Correlation of MVD and TIC parameters in ovarian tumors. (A) MVD was positively correlated with PI, and (B) 
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